• WDR36, Glycolysis, and Human Blastoid Formation

  2026-10-05

  A 2025 Advanced Science study links WDR36 to trophectoderm differentiation in human stem-cell-derived blastoids through glucose metabolism and an interaction with LDHA. The findings provide a mechanistic framework for studying early developmental arrest, while remaining preclinical because blastoids are models rather than implanted human embryos.

• D-Lin-MC3-DMA Product Overview

  2026-10-05

  D-Lin-MC3-DMA, also written Dlin-MC3-DMA, is listed by APExBIO as an ionizable cationic liposome lipid for conceptual use in nucleic-acid delivery research. No matched paper evidence was provided, so performance, safety, and application claims remain unverified here.

• miR-424/503 Links TGF-β to CDC25A Arrest

  2026-10-04

  The reference study identifies the miR-424/503 cluster as a post-transcriptional component of TGF-β-induced cell-cycle arrest in mammary epithelial cells. Its findings show that microRNA-mediated CDC25A suppression works alongside transcriptional repression and proteasomal degradation, refining the mechanistic model of TGF-β cytostasis.

• Annexin V-HF647/PI Apoptosis Kit in ESCC

  2026-10-03

  Explore how the Annexin V-HF647/PI Apoptosis Kit can support careful interpretation of apoptosis-associated phenotypes in esophageal squamous cell carcinoma. This article connects dual-parameter cell-death readouts with the HOXC9–AKT/mTOR findings while clarifying what the assay can—and cannot—prove.

• 4-Hydroxytamoxifen: Protocol and QC Guide

  2026-10-02

  This guide explains how to prepare and control 4-Hydroxytamoxifen (SKU B6167) for DMSO-based estrogen receptor modulation, cancer, apoptosis, and cardiac myocyte workflows. It is not appropriate for protocols requiring water or ethanol solubility, and the supplied dossier does not establish a universal concentration, exposure time, or endpoint.

• Angiotensin 1/2 (5-7): Assay Design Guide

  2026-10-01

  Explore Angiotensin 1/2 (5-7), the H2N-Ile-His-Pro-OH peptide, through a practical framework for RAS, cardiovascular, and spike–receptor binding assays. This guide emphasizes fragment-aware controls, product handling, and the limitations of translating binding data into disease mechanisms.

• BRD4770 and the Translational Logic of G9a Inhibition

  2026-10-01

  BRD4770 offers a mechanism-first way to interrogate G9a/EHMT2, H3K9 methylation, senescence, and cancer-cell proliferation. This article connects evidence from breast cancer pathway studies with PANC-1 research, while defining practical validation steps, translational boundaries, and opportunities for more rigorous epigenetic model selection.

• GSTA1, Glutathione Loss, and α-Amanitin Toxicity

  2026-09-30

  A 2026 study identifies GSTA1 as an unexpected driver of α-amanitin hepatotoxicity rather than a purely protective antioxidant enzyme. Through integrated omics, interaction studies, and genetic silencing, the work links NRF2-associated GSTA1 upregulation to glutathione depletion, reactive oxygen species accumulation, and hepatocyte injury.

• SUMO Protease (Ulp): Practical Cleavage Workflow

  2026-09-30

  SUMO Protease (Ulp) is a recombinant Ulp1 protease for removing SUMO fusion tags after affinity purification, enabling downstream protein structural and functional analysis. It is intended for SUMO-tagged constructs with the appropriate C-terminal Gly-Gly junction, not for unrelated affinity tags or nonspecific protein degradation.

• Z-LEHD-FMK: Precision Caspase-9 Inhibition

  2026-09-29

  Z-LEHD-FMK helps separate caspase-9-dependent mitochondrial apoptosis from downstream executioner activity in cell, ischemia/reperfusion, cancer, and neuroprotection workflows. This guide combines time-resolved assay design, formulation guidance, orthogonal readouts, and troubleshooting for more interpretable apoptosis experiments.

• When HRP Proximity Labeling Meets Serotonin

  2026-09-29

  Biotin-XX Tyramide Reagent enables membrane-impermeant HRP-mediated labeling of extracellular targets, but serotonin can suppress this chemistry in neuronal proximity-labeling workflows. This thought-leadership article connects the mechanistic finding to assay design, tyramide signal amplification, tissue imaging, and translational research strategy.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody Workflow

  2026-09-28

  Build a reproducible fluorescence workflow around the Cy3 Goat Anti-Mouse IgG (H+L) Antibody for mapping RNLS–PMCA4b signaling in NCI-H295R cells. The guide connects receptor-localization imaging with flow cytometry, western blotting, and controls that distinguish fluorescence from true pathway effects.

• SpCas9 mRNA: A Translation-Aware Editing Strategy

  2026-09-28

  SpCas9 mRNA enables guide-directed editing while separating Cas9 delivery from DNA-vector expression. This article explains how its RNA design shapes experimental interpretation—and why cap-independent translation research should not be confused with performance evidence for capped Cas9 mRNA.

• RNA-Triggered Pyroptosis with Type III-E CRISPR

  2026-09-27

  The study introduces DAMAGE, a synthetic system that links target-RNA recognition by a type III-E CRISPR effector to gasdermin-mediated pyroptosis. Its findings establish a programmable strategy for eliminating selected transcriptome-altered cells, while leaving important questions about specificity, delivery, and therapeutic safety for further study.

• Actinomycin D Workflows for RNA Stability

  2026-09-26

  Use Actinomycin D to separate altered mRNA decay from changes in transcription, with a practical chase design informed by diabetic vascular calcification research. This guide covers dose selection, solvent handling, controls, interpretation, and ways to limit confounding from transcriptional stress and cytotoxicity.

7991 records 1/533 page Next 12345 下5页 Last page